Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One ...

IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TARS), today announced that management will participate in ...

The partnership brings Darktrace's advanced cybersecurity and self-learning AI technology to customers across Africa.

Local technology distributor Tarsus Distribution has announced that it will be bring the Self-Learning AI technology from cybersecurity firm Darktrace to African enterprises.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.0, a high estimate of $72.00, and a low estimate of $41.00. Surpassing the previous average ...

The president offered a proclamation Saturday to begin duties on Canada, Mexico, and China. Musk says Tesla's robotaxis will hit Austin this summer. But after years of unfulfilled promises, investors ...

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its price objective lifted by equities researchers at Barclays from $60.00 to $62.00 in a research note issued on Monday,Benzinga reports.

Tarsus Pharmaceuticals, Inc. has announced plans to advance TP-04, an investigational ophthalmic gel formulation of lotilaner, for the treatment of Ocular Rosacea, a significant but currently ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today provided an update on the Company’s key priorities for 2025, including plans to advance TP-04 for the ...

Barclays analyst Balaji Prasad raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $62 from $60 and keeps an Overweight rating ...